Summit Creek Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Summit Creek Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,935	Closed	-$320K	–	73
2023 Q1	$320K	Sell	2,935 -1,381	-32%	-$153K	0.04%	64
2022 Q4	$491K	Sell	4,316 -801	-16%	-$66.5K	0.07%	57
2022 Q3	$317K	Sell	5,117 -3,677	-42%	-$257K	0.04%	61
2022 Q2	$701K	Sell	8,794 -1,818	-17%	-$172K	0.09%	59
2022 Q1	$1.12M	Buy	10,612 +1,099	+12%	+$107K	0.13%	53
2021 Q4	$1.02M	Buy	9,513 +19	+0.2%	+$2.07K	0.1%	61
2021 Q3	$1.04M	Buy	9,494 +4,140	+77%	+$430K	0.11%	59
2021 Q2	$501K	Buy	5,354 +2,100	+65%	+$193K	0.06%	61
2021 Q1	$299K	Buy	+3,254	New	+$275K	0.04%	65
2020 Q4	–	Sell	-3,240	Closed	-$252K	–	72
2020 Q3	$252K	Buy	+3,240	New	+$223K	0.04%	71

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Summit Creek Advisors's HZNP Position: Q2 2023 in Review

Summit Creek Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 2,935 shares — an estimated $320K sold.

Summit Creek Advisors first reported a position in HZNP in Q3 2020 and held it in 10 quarters. The position peaked at $1.12M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Summit Creek Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Summit Creek Advisors sold 2,935 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $320K.
Summit Creek Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 10 quarters.
Summit Creek Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.12M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Summit Creek Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.